Company intelligence / Profile preview

Universal Diagnostics

Seville, Andalusia, Spainuniversaldx.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Universal Diagnostics has demonstrated that its blood-based test Signal-C® can detect colorectal cancer at 91–92% sensitivity and 92–94% specificity in large international case-control studies. The test also detects pre-cancerous advanced adenomas with moderate sensitivity. These results have been presented at major scientific conferences and support the potential of their technology for population-level screening to reduce colorectal cancer incidence and mortality[2][8].

Therapeutic areas: Oncology
Modalities: Diagnostic testMulti-omics platform
Industry: Molecular Diagnostics

Drug pipeline

3 assets

Signal-C

Phase 3

Indications: Colorectal cancer

2 more assets in the full pipeline.

Request access →

Partnerships

Quest Diagnostics IncorporatedOlympus Innovation Ventures LLC

Beyond the preview

Go deeper on Universal Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Universal Diagnostics.

Explore the full profile